•BioFire FilmArray BCID2 panel enable earlier agent identification and detection of resistance genes compared to conventional culture methods.•BioFire FilmArray BCID2 panel appropriate antibiotherapy modifications and infection control measures could be taken earlier compared to traditional culture methods.•The use of BioFire FilmArray BCID2 panel is promising in critical bacteremia patient. The BioFire FilmArray Blood Culture Identification panel (BCID2), a rapid molecular blood culture identification test based on multiplex nested polymerase chain reaction. The aim of this study was to evaluate clinical outcomes between the period before (pre-BCID2 group) and after (post-BCID2 group) the introduction of the BCID2 panel into our routine practice. The primary endpoint was time to optimal antibiotherapy, and the secondary endpoints were duration of hospital and intensive care unit stay, 7-day, 14-day and 28-day mortality rates after bacteremia. The median time from empirical antibiotherapy to optimal antimicrobial therapy was 4560 (IQR;3060-7140) minutes in the pre-BCID2 group and 1715 (IQR;1362- 2776.25) minutes (in the post-BCID2 group (p<0.05). Adding the BCID2 panel may improve antibiotic management in critically ill bacteremia patients